Foghorn reports preclinical AACR data for FHD-909, CBP/EP300 degraders; IND on track Q2 2024

Foghorn Therapeutics Inc.

FHD-909, a first-in-class BRM selective inhibitor, shows ~30-fold selectivity over BRG1 and dose-dependent tumor growth inhibition in BRG1 mutant xenografts.
IND filing for FHD-909 in BRG1-mutant NSCLC on track for Q2 2024; developed with Lilly.
Selective CBP degrader demonstrates tumor growth inhibition in solid tumors without thrombocytopenia or anemia.
Selective EP300 degrader shows efficacy in prostate cancer and DLBCL models with no platelet effects.
Conference call today at 5 pm ET to review pipeline updates.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.